Evofem Biosciences, Inc.

Thank you for standing by, and welcome to the EvoFem Biosciences fourth quarter and year-end 2021 results conference call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will be a question-and-answer session. To ask a question at that time, please press star then 1 on your touch-tone telephone. As a reminder, today's conference call is being recorded. I will now turn the conference over to your host, Ms. Amy Raskoff, Vice President of Investor Relations. Ma'am, you may begin. Thank you.

Thank you, Valerie. Good afternoon, everyone, and welcome to the FFM biosynthesis Q4 and year-end 2021 results call. If you haven't done so already, I encourage you to access the press release we issued this afternoon and slides that accompany this call, both of which are at FFM.com under the Investors tab. Before we begin, I would like to remind you that remarks made on this call will contain forward-looking statements, which are made only as of today, March 3, 2022. For a more detailed description of important risk factors that could cause our actual results to differ materially, please refer to our annual report on Form 10-K and our most recently filed 10-Q. With that, I'll turn the call over to EvoFem's CEO, Sandra Pelletier. Thank you, Amy, and I want to thank everyone for joining us today on the call.

EvoFem delivered strong growth in the fourth quarter of 2021. Net product sales of Phexy for hormone-free birth control more than doubled in Q4. It increased 109% to 3.6 million. This reflects the hard work of our sales organization, the impact of our innovative marketing campaign, and ongoing growth to net improvements. We are excited to build on this foundation in 2022 and beyond. Additionally, we made significant progress in our program developing VEXI for the prevention of chlamydia and gonorrhea. Today, literally today, We completed enrollment in our Registrational Phase III EvoGuard trial ahead of the schedule we discussed on our Q3 earnings call with more participants than called for in the study protocol. This was due to very strong interest in the trial and high screening levels. We also received qualified infectious disease product designation from the FDA for prevention of chlamydia. This affords us five years additional market exclusivity on approval. I'll discuss next steps for this program in greater detail amongst other initiatives to build shareholder value after our CFO, Jay, files, reviews the financial results.